Cancer Protein Biomarkers

Answer the most difficult questions in cancer

Oncology biomarker research is about translating progress made in identifying relevant biomarkers in basic research into cancer therapeutics that potentially benefit patients. Our approach uses mass spectrometry as the discovery engine to discover new oncogenic or tumorgenic biomarkers. Cancer research techniques using mass spectrometry can be used to discover and validate biomarkers that can be used for early detection of cancer, proteomics in cancer prognostics, proteogenomics and monitoring response to therapy.

The versatile nature of mass spectrometry gives cancer researchers the flexibility in using any type of clinical sample including cell lines, tumor tissue, serum, plasma, urine, saliva, NAF for breast cancer.

Speak to a specialist

Unless otherwise noted, all products are for research use only, not for use in diagnostic procedures.

Cancer biomarker research

With access to our innovative products and platforms, you can answer all the leading questions one would face when performing cancer research.

Bringing together the worlds of biology and chemistry with new technologies

Advances in mass spectrometry and separation science are bringing genome-scale proteomic analyses within our reach. Thomas Conrads, Associate Director of Scientific Technologies in the Inova Schar Cancer Institute, describes how his lab applies the power of proteomic tools to help women with cancer.

Learn more about protein biomarker discovery through validation using mass spectrometry ›

Featured oncology research products

Sample Preparation

Reliable sample prep so you can focus on what’s important to you.

Sample Separation

Separation solutions to match your workflow expectations.

Mass Spectrometry

Your partner in cancer biomarker research validation and verification.

Software & LIMS

Easy-to-use software and data systems to support your oncology research needs.

Webinars

Biomarker Discovery

Translating Proteomics into Clinical Diagnostics

Dr. Eleftherios P. Diamandis, MD, PhD, FRCP(C) with Mount Sinai Hospital, Dept. of Pathology & Laboratory Medicine & the Lunefel-Tanenbaum Research Institute, discusses his approach to using LCMS technology to identify potential biomarkers and how it may apply utility
in the future of clinical diagnostics.

View webinar

Using Translational Research Workflows

Detection of Pathogen Induced Cancer in a Human T-Cell Leukemia Virus Type 1 Disease Model on LC-HRAM Platform

Dr. Sucharita Dutta, Senior Research Associate at the Eastern Virginia Medical School discusses the Human T-Cell Leukemia Virus Type 1 (HTLV-1) as the potential factor for the development of an aggressive lymphoma, Adult T-cell Leukemia (ATL).

Meet our oncology collaborators